Search Videos and More
Symposium
2024 American Society of Clinical Oncology (ASCO)
Review presentations, oral abstracts, and other information shared by Dana-Farber physician-scientists at the ASCO 2024 Annual Meeting.
News
New $15 Million Grant to Dana-Farber Scientists Supports Research into Innovative Approaches to Endometrial Cancer Treatment
Physician-scientists at Dana-Farber Cancer Institute have received a five-year, $15 million Program Project Grant from the National Cancer Institute (NCI) for research in endometrial cancer, which arises in the inner lining of the uterus and strikes more than 68,000 women a year in the U.S.
News
Dana-Farber Research Publication 05.01.2024
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Unraveling the Menin Mystery to Halt Cancer Growth
The story of research in menin and its relation to cancer — from early efforts to understand how the cell makes use of menin, to explorations of the cell machinery operated by menin, to the development and testing of agents that inhibit menin, to work on preventing resistance to such agents — weaves through Dana-Farber at every step.
News
Dana-Farber Researchers Explore AI's Potential Roles in Predicting and Diagnosing Cancer
In 2022 and 2023, you couldn't go a day without hearing about artificial intelligence (AI). Generative AI tools such as chatbots and art generators had become a central topic in everyday conversations. But AI in cancer has deeper roots. Twenty-five years before ChatGPT burst onto the scene, computers started playing a larger role in cancer diagnostics. In 1997, mammograms weren't even digital yet, but computers had started analyzing them. The tools, called expert systems, used hard-coded logic to read digital images of X-ray-based mammograms to look for signs of cancer.
Document
Treatment Guideline: Use of Low-Dose Tamoxifen in Patients with Estrogen Receptor-Positive (ER+) Ductal Carcinoma in Situ (DCIS)
The Breast Oncology Center at Dana-Farber Brigham Cancer Center developed expert-based consensus recommendations for the use of low-dose tamoxifen in patients with Ductal Carcinoma in Situ (DCIS).
News
Ancient DNA Reveals Origin of Racial/Ethnic Disparity in a Childhood Cancer
There are 40% more Hispanic/Latino kids diagnosed with acute lymphoblastic leukemia (ALL) than white non-Hispanic/Latino children; actually, Hispanic/Latino individuals have the highest risk of ALL in the United States. However, the basis for this difference is not well understood. Researchers recently identified a genetic variant that accounts for the increased risk of B-cell ALL in Hispanic/Latino children, and using ancient DNA, they traced the mutation all the way back to the first migrants who entered the Americas ~13,000 years ago.
News
Breast Cancer Trial Aims to Improve Treatment for Men
Over the past 30 years, outcomes have improved dramatically for women with breast cancer. There are many new treatments, including hormone therapies and CDK4/6 inhibitors. In contrast, there has been no improvement in the outcomes for men with breast cancer. And current guidelines don’t support the use of newer therapies in men. Male breast cancer accounts for just 1% of all cases of breast cancer. Advancing care for a rare group requires a focused effort, so Jose Pablo Leone, MD, has invested energy into designing and leading a clinical trial for men with breast cancer.
News
Fox Chase Cancer Center Recognizes Nobel Laureate Dr. William Kaelin With the Stanley P. Reimann Honor Award
William Kaelin Jr., MD, physician, scientist, and Nobel laureate, was recognized today at Fox Chase Cancer Center with the Stanley P. Reimann Honor Award, the center’s highest distinction. The award was presented to Kaelin while he was visiting Fox Chase to deliver a scheduled lecture.
News
Dana-Farber Cancer Institute Launches Neuro-Inclusive Oncology Care and Empowerment Program
Dana-Farber Cancer Institute launched the Neuro-Inclusive Oncology Care and Empowerment Program, a psychosocial oncology program that is specialized for adults with intellectual and/or developmental disabilities (IDD).
News
Gordon J. Freeman, PhD, Recognized with 2024 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
Gordon J. Freeman, PhD, of Dana-Farber Cancer Institute, will receive the 2024 AACR-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology from the American Association for Cancer Research (AACR).
News
Palliative Care Leader Receives Prestigious ASCO Special Award